The Role of TEVIMBRA (tislelizumab-jsgr)

When:  Apr 17, 2025 from 18:00 to 20:00 (CT)
Associated with  Southeast Minnesota
Join us for a 60-minute discussion on the role of TEVIMBRA (tislelizumab-jsgr), a newly approved immunotherapy specifically designed to optimize PD-1 binding and deliver more robust T-cell activation.

Using a case-based approach, we will explore key clinical data and discuss treatment decision-making as well as key considerations for optimizing patient care. This session is designed for medical oncologists and other healthcare professionals to deepen their understanding of TEVIMBRA and its use in the management of ESCC and GC/GEJC.

Thursday, April 17, 2025
6:00PM CDT

 Five West Kitchen & Bar
1991 Commerce Dr. NW
Rochester, MN 55901 

Kirollos Hanna FACC, PharmD, BCOP, BCPS
Minnesota Oncology - St. Paul

To RSVP: 
Rep: Scott Nelson
Phone: 612-385-7386
Email: scott.nelson@beonemed.com

or RSVP with link: EventView
More information

Location

Five West
1991 Commerce Dr. NW
Rochester, MN 55901

Contact

Scott Nelson
612-385-7386
scott.nelson@beonemed.com